– Annamycin in combination with Cytarabine achieves CRc rate of 60% in 2nd line AML subjects
– AnnAraC has potential to fill significant unmet need and expected to increase 2nd.
– MB-106 AML Phase 1B/2 trial (MB-106) preliminary data readout: Reached 67% recruitment – MB-106 preliminary results: Intent to Treat CR rate of 40% plus a.
– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML.